Литература

Поставить закладку

1. Sussman H.H. Iron in cancer. Pathobiology. 1992, 60, p. 2-9.
2. Finch C.A., Huebers H.A. Iron metabolism. Clin. Physiol.Biochem. 1986, 4, p. 5-15.
3. Лукина Е.А., Деженкова А.В. Метаболизм железа в норме и при патологии // Клиническая онкогематология - 2015. - №4. - С.355-361
4. Adams PC. Hemochromatosis. Clin Liver Dis 8: 735-753, 2004.
5. Cabantchik Z. Y., Brener W, Zanninelili G. LPY-labile plasma iron in iron overload. Best Pract Res Clin Haematol 18: 277-287, 2005.
6. Denz H., Orth B., Huber P. at al. Immune activation and anemia of chronic disorders. Blood. 1993, 81, p. 1404-1409.
7. Ganz T. Hepcidin - a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 18: 171-182, 2005.
8. Ilickstein H, El R. B., Shvartsman M, Cabantchik Z. Y. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 106: 32423250, 2005.
9. Means R.T,, Krantz S.B. Progress in understanding the pathogenesis of anemia of chronic disease. Blood, 1992, 80, 1639-1644.
10. Kuntz E., Kuntz H-D. Haemochromatosis. In: “Hepatology - Principles and Practice”. 2002, Springer-Verlag Berlin, p.556-565.
11. Mims MP, Guan Y, Pospisilova D, et al. Identification of a human mutation of DMT 1 in a patient with microcytic anemia and iron overload. Blood 103: 1337-1342, 2005.
12. Ponka P. Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood 89: 1-25, 1997.
13. Porter J.B. Monitoring and treatment of iron overload: state of the art and new approaches. Sem.Hematol. 2005. v.42, 2, suppl. 1, p.14-18.
14. Roetto A, Camaschella C. New insights into iron homeostasis through the study of non-HFE hereditary haemochromatosis. Best Pract Res Clin Haematol 18: 235-250, 2005
15. Sarigianni M, Liakos A, ^,Vlachaki E, Paschos P. et al. Accuracy of magnetic resonance imaging in diagnosis of liver iron overload: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015 Jan;13(1):55-63.e5. doi: 10.1016/j.cgh.2014.05.027. Epub 2014 Jun 30
16. Xia S, Zhang W, Huang L, Jiang H. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. PLoS One. 2013 Dec 23;8(12):e82662. doi: 10.1371/journal.pone.0082662.
17. Maggio A, Filosa A, Vitrano A, et al. Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis. 2011 Oct 15;47(3):166-75. doi: 10.1016/j.bcmd.2011.07.002.
18. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009 Dec;147 (5):752-9. doi: 10.1111/j.1365-2141.2009.07908.x.
19. Bollig C1, Schell LK, Rucker G, et al. Deferasirox for managing iron overload in people with thalassaemia. Cochrane Database Syst Rev.2017, Aug.,15;8, CD007476 doi: 10.1002/14651858.CD007476.pub3.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница